| 臺大學術典藏 |
2020-10-14T06:31:09Z |
Tumor necrosis factor-α-238 and -308 polymorphisms do not associate with traits related to obesity and insulin resistance
|
Andersen R.E.; CHUNG-JEN YEN; Cheskin L.J.; Seibert M.; Walston J. |
| 亞洲大學 |
2004 |
Tumor necrosis factor-α-308 promoter and p53 codon 72 gene polymorphisms in women with leiomyomas
|
Hsieh Yao-Yuan;Chi-Chen Chang;Fuu-Jen Tsai;Cheng-Chieh Lin;Lian-Shung Yeh;Chang-Hai Tsai |
| 中國醫藥大學 |
2004 |
Tumor necrosis factor-α-308 promoter and p53 codon 72 gene polymorphisms in women with leiomyomas
|
謝耀元; 張其真(Chi-Chen Chang); 蔡輔仁(Fuu-Jen Tsai)*; 林正介(Cheng-Chieh Lin); 葉聯舜(Lian-Shung Yeh); 蔡長海(Chang-Hai Tsai) |
| 臺大學術典藏 |
2020-03-05T03:20:29Z |
Tumor necrosis factor-α-elicited stimulation of γ-secretase is mediated by c-Jun N-terminal kinase-dependent phosphorylation of presenilin and nicastrin
|
WEN-MING HSU; Tung Y.-T.; Wang B.-J.; Tsai W.-W.; Yen C.-T.; Liao Y.-F.; Kuo L.-H.; Hu M.-K. |
| 臺大學術典藏 |
2018-09-10T07:10:03Z |
Tumor necrosis factor-α-elicited stimulation of γ-secretase is mediated by c-Jun N-terminal kinase-dependent phosphorylation of presenilin and nicastrin
|
Kuo, L.-H.;Hu, M.-K.;Hsu, W.-M.;Tung, Y.-T.;Wang, B.-J.;Tsai, W.-W.;Yen, C.-T.;Liao, Y.-F.; Kuo, L.-H.; Hu, M.-K.; Hsu, W.-M.; Tung, Y.-T.; Wang, B.-J.; Tsai, W.-W.; Yen, C.-T.; Liao, Y.-F.; WEN-MING HSU; CHEN-TUNG YEN |
| 臺大學術典藏 |
2021-05-07T05:13:45Z |
Tumor necrosis factor-αinduced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and lκb kinase 1/2 in human alveolar epithelial cells
|
CHING-CHOW CHEN; Sun Y.-T.; Chen J.-J.; Chang Y.-J. |
| 臺大學術典藏 |
2008 |
Tumor Necrosis Factor-α–elicited Stimulation of γ-Secretase Is Mediated by c-Jun N-terminal Kinase-dependent Phosphorylation of Presenilin and Nicastrin
|
Kuo, Lan-Hsin; Hu, Ming-Kuan; Hsu, Wen-Ming; Tung, Ying-Tsen; Wang, Bo-Jeng; Tsai, Wang-Wei; Yen, Chen-Tung; Liao, Yung-Feng; Kuo, Lan-Hsin; Hu, Ming-Kuan; Hsu, Wen-Ming; Tung, Ying-Tsen; Wang, Bo-Jeng; Tsai, Wang-Wei; Yen, Chen-Tung; Liao, Yung-Feng |
| 國立臺灣大學 |
2008 |
Tumor Necrosis Factor-α–elicited Stimulation of γ-Secretase Is Mediated by c-Jun N-terminal Kinase-dependent Phosphorylation of Presenilin and Nicastrin
|
Kuo, Lan-Hsin; Hu, Ming-Kuan; Hsu, Wen-Ming; Tung, Ying-Tsen; Wang, Bo-Jeng; Tsai, Wang-Wei; Yen, Chen-Tung; Liao, Yung-Feng |
| 國立臺灣大學 |
2001-12 |
Tumor necrosis factor--induced apoptosis in cord blood T lymphocytes: involvement of both tumor necrosis factor receptor types 1 and 2
|
Yang, Ya-Chien; Hsu, Tsuey-Ying; Chen, Jen-Yang; Yang, Czau-Siung; Lin, Rong-Hwa |
| 臺大學術典藏 |
2020-11-02T02:05:30Z |
Tumor necrosis factor-�\ and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma
|
Wang H.-P.; Lin J.-T.; Lin M.-T.; Chang M.-C.; Shun C.-T.; Chang Y.-T.; Huang S.-P.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:47:56Z |
Tumor necrosis factor: The key to hepatitis B viral clearance
|
Chyuan I.-T.; PING-NING HSU |
| 中國醫藥大學 |
2014-08-28 |
Tumor necrosis factors, molds and Asthma in Children: A Haplotype-Based Analysis.
|
黃鈺斯(Yu-Sih Huang);李郁芬(Yu-Fen Li);戴婷豫(Ting-Yu Tai);林育廷(Yu-Ting Lin);黃彬芳(Bing-Fang Hwang);黃彬芳(Bing-Fang Hwang) |
| 國立臺灣大學 |
2001 |
Tumor necrosis factor-induced activation of downstream NF-kB site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion: Involvement of PKC, tyrosine kinase and IKK2, but not MAPKs
|
Chen, Ching-Chow; Chou, Chian-Ying; Sun, Yi-Tao; Huang, Wei-Chien |
| 國立成功大學 |
2021-07 |
Tumor Necrosis with Adjunction of Preoperative Monocyte-to-Lymphocyte Ratio as a New Risk Stratification Marker Can Independently Predict Poor Outcomes in Upper Tract Urothelial Carcinoma
|
Lin;Kun-Che;Jan;Hau-Chern;Hu;Che-Yuan;Ou;Yin-Chien;Kao;Yao-Lin;Yang;Wen-Horng;Ou;Chien-Hui |
| 國立臺灣大學 |
2007-11 |
Tumor necrotizing factor-a and GST-T1 genotype predict skin allergy to chromate in cement workers in Taiwan
|
Wang, BJ; Shiao, JSC; Chen, CJ; Lee, YC; Guo, YL |
| 臺大學術典藏 |
2019-03-04T08:13:58Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin, Shu Yung;Yang, Ching Yao;Bin-Chi Liao;Chao-Chi Ho;Wei-Yu Liao;Chen, Kuan-Yu;Tsai, Tzu Hsiu;Chia-Lin Hsu;Hsu, Wei Hsun;Kang-Yi Su;Yih-Leong Chang;Lee, Jih Hsiang;Lin, Chia Chi;Jin-Yuan Shih;Yang, James Chih Hsin;Chong-Jen Yu; Lin, Shu Yung; Yang, Ching Yao; BIN-CHI LIAO; CHAO-CHI HO; WEI-YU LIAO; Chen, Kuan-Yu; Tsai, Tzu Hsiu; CHIA-LIN HSU; Hsu, Wei Hsun; KANG-YI SU; YIH-LEONG CHANG; Lee, Jih Hsiang; Lin, Chia Chi; JIN-YUAN SHIH; Yang, James Chih Hsin; Chong-Jen Yu |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Yih-Leong Chang;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:57Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:21Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; Tsai T.-H.; Chen K.-Y.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Yu C.-J.; Yang J.C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Anonymous |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
